OpenAI and Thermo Fisher Partner to Accelerate Drug Development
The collaboration will embed OpenAI's models into the life sciences company's clinical research business to improve the speed and success of clinical trials.
Embedding AI in Life Sciences
Thermo Fisher Scientific and OpenAI announced a collaboration to embed artificial intelligence into the life sciences company's operations. The partnership will focus on using OpenAI's models to improve the speed and success of drug development, helping customers get new medicines to patients faster and more cost-effectively.
"With OpenAI directly powering Thermo Fisher workflows, frontier AI can help cut through complexity, speed up breakthroughs, and bring real impact to patients' lives,” said Brad Lightcap, chief operating officer at OpenAI. The collaboration will integrate OpenAI's APIs into critical areas of Thermo Fisher's business.
A Focus …
Archive Access
This article is older than 24 hours. Create a free account to access our 7-day archive.